Darusentan Data to Be Presented at AHA 2006 -- Chicago

  
    
  
  
    
      Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the 
      discovery, development and commercialization of small molecule 
      therapeutics for the treatment of cardiovascular disorders, today 
      announced that an abstract describing the effects of darusentan on 
      resistant hypertension has been selected for oral presentation at the 
      American Heart Association Scientific Sessions conference to be held 
      Nov. 12-15, 2006, at the McCormick Place Convention Center in Chicago, 
      Ill.
    
    
      Michael Weber, M.D., will present “Darusentan 
      Significantly Reduces Systolic Blood Pressure in Patients with Resistant 
      Hypertension on Four or More Antihypertensive Drugs.” 
      The presentation is scheduled for Monday, Nov. 13, 2006, from 2:15 p.m. 
      to 2:30 p.m. Dr. Weber is an Associate Dean and Professor of Medicine at 
      the State University of New York Health Science Center in Brooklyn, 
      N.Y., and is a member of the clinical advisory group for the darusentan 
      development program.
    
    
      Myogen has two product candidates in late-stage clinical development: 
      ambrisentan for the treatment of patients with pulmonary arterial 
      hypertension (PAH) and darusentan for the treatment of patients with 
      resistant hypertension. Myogen and GlaxoSmithKline have entered into a 
      global PAH collaboration in which Myogen has marketing and distribution 
      rights to GlaxoSmithKline's Flolan® 
      (epoprostenol sodium) for injection in the United States and 
      GlaxoSmithKline has licensed ambrisentan from Myogen for all territories 
      outside of the United States, where Myogen retains exclusive rights. 
      Myogen also conducts a target and drug discovery research program 
      focused on the development of disease-modifying drugs for the treatment 
      of chronic heart failure and related cardiovascular disorders. Please 
      visit Myogen's website at www.myogen.com.
    
    
      Safe Harbor Statement
    
    
      The anticipated presentation will contain forward-looking statements 
      that involve significant risks and uncertainties, including those to be 
      discussed in the presentation and others that can be found in the “Risk 
      Factors” section of Myogen’s 
      Form 10-K for the year ended December 31, 2005 and Myogen’s 
      periodic reports on Form 10-Q and Form 8-K. Results from clinical 
      trials, including the Company's Darusentan Phase 2b trial, are not 
      necessarily predictive of future clinical results. Myogen does not 
      undertake any obligation to update any forward-looking statements 
      contained in the anticipated presentation as a result of new 
      information, future events or otherwise. The company cautions investors 
      not to place undue reliance on the forward-looking statements contained 
      in this press release or the presentation. No forward-looking statement 
      can be guaranteed and actual events and results may differ materially 
      from those projected.
    
  
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused
on the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that an abstract describing the effects of darusentan on
resistant hypertension has been selected for oral presentation at the
American Heart Association Scientific Sessions conference to be held
Nov. 12-15, 2006, at the McCormick Place Convention Center in Chicago,
Ill.

   Michael Weber, M.D., will present "Darusentan Significantly
Reduces Systolic Blood Pressure in Patients with Resistant
Hypertension on Four or More Antihypertensive Drugs." The presentation
is scheduled for Monday, Nov. 13, 2006, from 2:15 p.m. to 2:30 p.m.
Dr. Weber is an Associate Dean and Professor of Medicine at the State
University of New York Health Science Center in Brooklyn, N.Y., and is
a member of the clinical advisory group for the darusentan development
program.

   Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH collaboration in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol
sodium) for injection in the United States and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States, where Myogen retains exclusive rights. Myogen also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com.

   Safe Harbor Statement

   The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties, including
those to be discussed in the presentation and others that can be found
in the "Risk Factors" section of Myogen's Form 10-K for the year ended
December 31, 2005 and Myogen's periodic reports on Form 10-Q and Form
8-K. Results from clinical trials, including the Company's Darusentan
Phase 2b trial, are not necessarily predictive of future clinical
results. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated presentation
as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those projected.